The Patent Finder

Basilea Pharmaceutica AG

Also on record
Records under this name other than the patents Basilea Pharmaceutica AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.

Back to Basilea Pharmaceutica AG

PatentTitleStatus Expires Confidence
US 9,163,034Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,865,697Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,995,754Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
Lapsed on the fee record
Ended Jun 12, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 12, 2026From the USPTO record
US 9,970,938Use of BUBR1 as a Biomarker of Drug Response to Furazanobenzimidazoles
Formerly held
Lapsed on the fee record
Ended May 15, 2026 · High confidence
Lapsed on the fee recordEnded May 15, 2026High confidence
US 6,812,238N-substituted carbamoyloxyalkyl-azolium derivatives
Formerly held
Term ended
Term ended Oct 31, 2025 · From the USPTO record
Term endedTerm ended Oct 31, 2025From the USPTO record
US 8,697,122Formulation for Retinoid-Containing Soft Gelatin Capsules
Formerly held
Term ended
Ended no later than Feb 19, 2025 · Medium confidence
Term endedEnded no later than Feb 19, 2025Medium confidence
US 8,093,377Cephalosporin in crystalline form
Term ended
Term ended Jan 17, 2025 · From the USPTO record
Term endedTerm ended Jan 17, 2025From the USPTO record
US 9,476,889Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
Lapsed on the fee record
Ended Oct 25, 2024 · From the USPTO record
Lapsed on the fee recordEnded Oct 25, 2024From the USPTO record
US 7,531,650Cephalosporin salts in crystalline form
Term ended
Term ended Oct 21, 2024 · From the USPTO record
Term endedTerm ended Oct 21, 2024From the USPTO record
US 9,084,823Formulation For Retinoid-Containing Soft Gelatin Capsules
Formerly held
Term ended
Ended no later than Oct 5, 2024 · Low confidence
Term endedEnded no later than Oct 5, 2024Low confidence
10 of 103 patents shown.
Pro members see all 103.
Pro members: see all 103 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited